Phosphatidic Acid Activates Mammalian Target of Rapamycin Complex 1 (mTORC1) Kinase by Displacing FK506 Binding Protein 38 (FKBP38) and Exerting an Allosteric Effect
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Phosphatidic acid (PA) is a critical mediator of mitogenic activation of mammalian target of rapamycin complex 1 (mTORC1) signaling, a master regulator of mammalian cell growth and proliferation. The mechanism by which PA activates mTORC1 signaling has remained unknown. Here, we report that PA selectively stimulates mTORC1 but not mTORC2 kinase activity in cells and in vitro. Furthermore, we show that PA competes with the mTORC1 inhibitor, FK506 binding protein 38 (FKBP38), for mTOR binding at a site encompassing the rapamycin-FKBP12 binding domain. This leads to PA antagonizing FKBP38 inhibition of mTORC1 kinase activity in vitro and rescuing mTORC1 signaling from FKBP38 in cells. Phospholipase D 1, a PA-generating enzyme that is an established upstream regulator of mTORC1, is found to negatively affect mTOR-FKBP38 interaction, confirming the role of endogenous PA in this regulation. Interestingly, removal of FKBP38 alone is insufficient to activate mTORC1 kinase and signaling, which require PA even when the FKBP38 level is drastically reduced by RNAi. In conclusion, we propose a dual mechanism for PA activation of mTORC1: PA displaces FKBP38 from mTOR and allosterically stimulates the catalytic activity of mTORC1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., & Chen, J. (2001) · Science · doi:10.1126/science.1066015 · Cited by 1,055
Self-citationRheb Binds and Regulates the mTOR Kinase
Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005
Rheb Activates mTOR by Antagonizing Its Endogenous Inhibitor, FKBP38
Bai, X., Ma, D., Liu, A., Shen, X., Wang, Q. J., Liu, Y., & Jiang, Y. (2007) · Science · doi:10.1126/science.1147379 · Cited by 382
Self-citationVilella-Bach, M., Nuzzi, P., Fang, Y., & Chen, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.7.4266 · Cited by 154
Self-citationRalA Functions as an Indispensable Signal Mediator for the Nutrient-sensing System
Maehama, T., Tanaka, M., Nishina, H., Murakami, M., Kanaho, Y., & Hanada, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805822200 · Cited by 80
PLD regulates myoblast differentiation through the mTOR-IGF2 pathway
Yoon, M.-S., & Chen, J. (2008) · Journal of Cell Science · doi:10.1242/jcs.022566 · Cited by 67
Cited by
Reprogramming of fatty acid metabolism in cancer
Koundouros, N., & Poulogiannis, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0650-z · Cited by 1,614
Regulation of mTORC1 by PI3K signaling
Dibble, C. C., & Cantley, L. C. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.06.002 · Cited by 836
AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control
González, A., Hall, M. N., Lin, S.-C., & Hardie, D. G. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.015 · Cited by 797
Growing knowledge of the mTOR signaling network
Huang, K., & Fingar, D. C. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.09.011 · Cited by 305
Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes
Takahara, T., Amemiya, Y., Sugiyama, R., Maki, M., & Shibata, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00679-2 · Cited by 300
The role of mammalian target of rapamycin (mTOR) in insulin signaling
Yoon, M.-S. (2017) · Nutrients · doi:10.3390/nu9111176 · Cited by 300
“PA specifically activates mTORC1 activity in vitro without affecting mTORC2 activity [26].”
BackgroundSelf-citationYou, J.-S., Lincoln, H. C., Kim, C.-R., Frey, J. W., Goodman, C. A., Zhong, X.-P., & Hornberger, T. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.531392 · Cited by 163
Bond, P. (2016) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-016-0118-y · Cited by 121
“Secondly, mechanical stimuli regulate mTORC1 by regulating levels of phosphatidic acid (PA), a diacylglycerol phospholipid which has been found to directly activate mTORC1 [73].”
Backgroundda Silva Rosa, S. C., Martens, M. D., Field, J. T., Nguyen, L., Kereliuk, S. M., Hai, Y., Chapman, D., Diehl-Jones, W., Aliani, M., West, A. R., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1821548 · Cited by 117
Phosphatidic acid: an emerging versatile class of cellular mediators
Kim, S.-C., & Wang, X. (2020) · Essays in Biochemistry · doi:10.1042/ebc20190089 · Cited by 94
Phosphatidic acid enhances mTOR signaling and resistance exercise induced hypertrophy
Joy, J. M., Gundermann, D. M., Lowery, R. P., Jäger, R., McCleary, S. A., Purpura, M., Roberts, M. D., Wilson, S. M., Hornberger, T. A., & Wilson, J. M. (2014) · Nutrition & Metabolism · doi:10.1186/1743-7075-11-29 · Cited by 76
Zhu, C., Boucheron, N., Müller, A. C., Májek, P., Claudel, T., Halilbasic, E., Baazim, H., Lercher, A., Viczenczova, C., Hainberger, D., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.036 · Cited by 65
Diacylglycerol kinases in T cell tolerance and effector function
Chen, S. S., Hu, Z., & Zhong, X.-P. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00130 · Cited by 44
“…phosphatidylinositol-4-phosphate 5-kinase (PIP5K) (Galandrini et al., 2005; Jarquin-Pardo et al., 2007; Micucci et al., 2008; Cockcroft, 2009; Yoon et al., 2011), spingosine kinase (SPHK ½), RAF1 (Ghosh et al., 1996; Shome et al., 1997; Rizzo et al., 1999, 2000; Andresen et al., 2002), and…”
New roles for Smad signaling and phosphatidic acid in the regulation of skeletal muscle mass
Goodman, C. A., & Hornberger, T. A. (2014) · F1000Prime Reports · doi:10.12703/p6-20 · Cited by 30
“Mechanistically, it has been reported that PA can directly activatemTORC1 kinase activity in vitro and this appears to be due to its ability to bind to the FKBP12-rapamycin binding (FRB) domain of mTOR [60,65,71,72].”
BackgroundMobley, C. B., Hornberger, T. A., Fox, C. D., Healy, J. C., Ferguson, B. S., Lowery, R. P., McNally, R. M., Lockwood, C. M., Stout, J. R., Kavazis, A. N., et al. (2015) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-015-0094-7 · Cited by 23
“[14] or inhibition of PA production [5] results in the increased and decreased phosphorylation of 4EBP-1, respectively.”
Background
Metadata
- Authors
- Yoon, M.-S., Sun, Y., Arauz, E., Jiang, Y., & Chen, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 286
- Issue
- 34
- Pages
- 29568-29574
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2012923473
- Cited by
- 134
- References
- 9
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.